Advancing the Medical Business Case for Digital Endpoints

In the rapidly evolving healthcare landscape, integrating sensor-based digital health technologies (sDHTs) into clinical trials has represented a paradigm shift with profound implications for the medical device industry. sDHTs, such as wearable devices, smartphones, and other sensor-based digital technologies, generate digital endpoints that offer a more nuanced and continuous assessment of patient outcomes than traditional methods. Incorporating digital endpoints in clinical trials has been shown to improve efficiency, reduce clinical trial timelines, and increase the accuracy and relevance of clinical trial data, while also accelerating the pace of innovation within the industry. But how do we capture digital endpoints’ value and return on investment (ROI) in clinical trials to increase their broader adoption? 

Overcoming the Barriers to Broader Adoption

Medical devices encompass a broad range of products, from simple instruments like thermometers to complex machines such as MRI scanners and implantables, and they play a critical role in diagnosing, monitoring, and treating diseases. However, developing and deploying these devices is heavily regulated, requiring extensive clinical trials to ensure their safety and efficacy. The high cost and time investment required for clinical trials is a major challenge in the medical device industry. Traditional trials involve complex logistics, including frequent patient visits, manual data collection, and lengthy data analysis and interpretation periods. These processes are not only costly but also time-consuming, often leading to delays in bringing new devices to market. Additionally, the reliance on sporadic and subjective data collection can compromise the quality and reliability of trial outcomes.

Enhancing Clinical Trials: The Promise of Digital Endpoints

On the other hand, digital endpoints, collected using sDHTs, such as wearables and mobile apps, provide continuous, real-time, and objective data offering a more comprehensive and accurate picture of a patient’s condition within natural settings. Integrating digital endpoints into clinical trials can address many of the industry’s current challenges, such as reducing the need for frequent in-person visits and lowering the logistical and financial burdens for both patients and researchers. This remote monitoring capability also allows trials to include more diverse and geographically dispersed patient populations, enhancing the generalizability of the results.
 
Digital endpoints also have the potential to improve the quality of data collected during clinical trials. Wearable devices and sensors provide continuous streams of objective data, capturing subtle changes in a patient’s health that might be missed with traditional methods. This comprehensive data collection leads to more robust and reliable trial outcomes, ultimately improving medical device safety and efficacy profiles.
 
Moreover, the patient-centric nature of digital endpoints aligns with the increasing demand for personalized healthcare. Patients can engage more actively in their own health management through real-time feedback and continuous monitoring, leading to better adherence to trial protocols and more relevant data for researchers.
 
While digital endpoints’ proven impact and future potential are undeniable, widespread utilization remains a challenge. Decision-makers lack clear value assessments, routine use cases, and efficient deployment strategies around digital endpoints, hindering their numerous benefits. Increasing adoption will mean quantifying the ROI of digital endpoints and helping organizations make the business case for ongoing investment into digital measures and increase their adoption in clinical trials. We, at The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) are taking on this challenge by convening a cross-disciplinary team of leaders across the pharmaceutical and medical technology (med-tech) industries to develop open source resources focused on advancing the adoption of digital measures in healthcare and clinical research. Teams within pharmaceutical and med-tech companies will be able to use open-source resources to make the business case for the inclusion of digital endpoints in clinical trials. 
 
Ultimately, this work will influence clinical trials evaluating medical devices, as broader use of digital endpoints in clinical trials may improve a trial’s operational efficiency, reduce costs, and lower patient and site burden. This has the potential to accelerate the pace of innovation within the medical device industry and bring therapeutics to market at a much faster rate. However, in addition to enhancing the development of medical devices, findings from this collaboration may also increase the use of medical devices that generate digital endpoints in clinical trials, thus enhancing their broader use in clinical research. The outcomes of this project will not only benefit clinical trial processes but also drive broader changes within the industry and we are proud to work alongside industry partners to advance the field.
 

---

Victoria Bangieva, PhD is a licensed clinical psychologist who works at the intersection of clinical science, technology, and advocacy to advance clinical research and healthcare through the integration of digital health solutions. Dr. Bangieva has over 8 years of experience in the digital health industry designing, developing, and disseminating digital measures and therapeutics. Through these efforts, Dr. Bangieva is dedicated to increasing the adoption of digital health solutions in routine care and clinical research.